$2.96
3.32% today
Nasdaq, Apr 02, 09:18 pm CET
ISIN
US8051111016
Symbol
SVRA
Sector
Industry

Savara, Inc. Stock price

$2.86
+0.54 23.28% 1M
-1.13 28.32% 6M
-0.21 6.84% YTD
-1.98 40.91% 1Y
+1.54 116.67% 3Y
+0.86 43.00% 5Y
-29.38 91.13% 10Y
Nasdaq, Closing price Tue, Apr 01 2025
+0.09 3.25%
ISIN
US8051111016
Symbol
SVRA
Sector
Industry

Key metrics

Market capitalization $490.83m
Enterprise Value $321.32m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 2.88
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-103.20m
Free Cash Flow (TTM) Free Cash Flow $-89.11m
Cash position $196.33m
EPS (TTM) EPS $-0.48
P/E forward negative
Short interest 12.03%
Show more

Is Savara, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.

Savara, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Savara, Inc. forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Savara, Inc. forecast:

Buy
88%
Hold
13%

Financial data from Savara, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 0.28 0.28
56% 56%
-
-0.28 -0.28
56% 56%
-
- Selling and Administrative Expenses 25 25
60% 60%
-
- Research and Development Expense 78 78
76% 76%
-
-103 -103
72% 72%
-
- Depreciation and Amortization 0.28 0.28
56% 56%
-
EBIT (Operating Income) EBIT -103 -103
72% 72%
-
Net Profit -96 -96
75% 75%
-

In millions USD.

Don't miss a Thing! We will send you all news about Savara, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Savara, Inc. Stock News

Neutral
Business Wire
6 days ago
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the fourth quarter and full year ending December 31, 2024 and provided a business update. “Completing submission of the BLA is an important milestone in potentially addressing the significant unmet need of peop...
Neutral
Business Wire
7 days ago
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it has entered into a loan and security agreement with Hercules Capital, Inc. (NYSE: HTGC), for up to $200 million. Access to the additional capital strengthens Savara's balance sheet following the submission of the Biol...
Neutral
Business Wire
7 days ago
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it has completed submission of the BLA to the FDA for MOLBREEVI as a treatment for aPAP. “Submission of the BLA marks an important milestone for the Company and the aPAP community,” said Matt Pauls, Chair and Chief Execu...
More Savara, Inc. News

Company Profile

Savara, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its products include AeroVanc, Molgradex, GM-CSF, and Aironite. The company was founded on April 27, 2017 and is headquartered in Austin, TX.

Head office United States
CEO Matthew Pauls
Employees 59
Founded 1995
Website www.savarapharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today